PE20220098A1 - Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo - Google Patents
Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismoInfo
- Publication number
- PE20220098A1 PE20220098A1 PE2022000024A PE2022000024A PE20220098A1 PE 20220098 A1 PE20220098 A1 PE 20220098A1 PE 2022000024 A PE2022000024 A PE 2022000024A PE 2022000024 A PE2022000024 A PE 2022000024A PE 20220098 A1 PE20220098 A1 PE 20220098A1
- Authority
- PE
- Peru
- Prior art keywords
- sialic acid
- high content
- ige
- receptor
- present
- Prior art date
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title abstract 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title abstract 6
- 239000000539 dimer Substances 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000009109 Fc receptors Human genes 0.000 title abstract 2
- 108010087819 Fc receptors Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000009490 IgG Receptors Human genes 0.000 abstract 2
- 108010073807 IgG Receptors Proteins 0.000 abstract 2
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 239000013076 target substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a un receptor Fc de IgE modificado que tiene un alto contenido de acido sialico y una composicion farmaceutica que lo comprende. El dimero polipeptidico que tiene un alto contenido de acido sialico de acuerdo con la presente invencion no solo tiene una excelente seguridad y persistencia en el cuerpo en comparacion con los anticuerpos anti-IgE usados convencionalmente, sino que tambien se une a la IgE muy fuertemente, lo que tiene la ventaja de un ciclo de administracion prolongado. Ademas, el dimero polipeptidico que tiene un alto contenido de acido sialico de acuerdo con la presente invencion es una sustancia diana unica de IgE y, a diferencia de los anticuerpos anti-IgE convencionales a los que se aplica el Fc de IgG1, no se une a un receptor Fc gamma. Por lo tanto, puede inhibir la liberacion de mediadores causada por la union al receptor Fc gamma en la superficie de los mastocitos, de modo que se pueden minimizar los efectos secundarios graves, como la aparicion de anafilaxia, que puede ser causada por la union entre la IgG1 y el receptor Fc gamma III en los mastocitos. Ademas, el dimero polipeptidico que tiene un alto contenido de acido sialico puede mantener una alta concentracion en la sangre incluso en el caso de la administracion subcutanea. Por consiguiente, el dimero polipeptidico que tiene un alto contenido de acido sialico de acuerdo con la presente invencion puede usarse de manera util para la prevencion o el tratamiento de enfermedades alergicas
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190082217 | 2019-07-08 | ||
| PCT/KR2020/008855 WO2021006599A1 (ko) | 2019-07-08 | 2020-07-07 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220098A1 true PE20220098A1 (es) | 2022-01-24 |
Family
ID=74115108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000024A PE20220098A1 (es) | 2019-07-08 | 2020-07-07 | Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220257693A1 (es) |
| EP (1) | EP3998279A4 (es) |
| JP (1) | JP2022539684A (es) |
| KR (2) | KR102561135B1 (es) |
| AU (1) | AU2020310003A1 (es) |
| BR (1) | BR112022000246A2 (es) |
| CA (1) | CA3145382A1 (es) |
| CL (1) | CL2021003401A1 (es) |
| IL (1) | IL289679A (es) |
| MX (1) | MX2022000285A (es) |
| PE (1) | PE20220098A1 (es) |
| TW (1) | TWI764191B (es) |
| WO (1) | WO2021006599A1 (es) |
| ZA (1) | ZA202200738B (es) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3067334A (en) | 1959-03-13 | 1962-12-04 | Garrett Corp | Driving and control means for a plurality of alternators |
| KR100475417B1 (ko) * | 1998-12-30 | 2005-07-18 | 씨제이 주식회사 | 시알산 함량이 높은 재조합 당단백질의 제조방법 |
| WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
| US7867491B2 (en) * | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
| DK2853545T3 (en) | 2008-09-17 | 2016-08-29 | Xencor Inc | Antibody specific for IgE |
| CN102695956B (zh) * | 2009-10-26 | 2015-12-09 | 基因泰克公司 | 用于检测对治疗性抗IgE抗体特异性的抗体的测定法及其在过敏反应中的用途 |
| WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| WO2014144621A2 (en) * | 2013-03-15 | 2014-09-18 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
| KR20150135148A (ko) * | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Ｆｃ融合高親和性ＩｇＥ受體α鏈 |
| KR101873201B1 (ko) * | 2015-06-11 | 2018-07-02 | 주식회사 제넥신 | 변형된 인터루킨-7 단백질 및 이의 용도 |
| KR101847169B1 (ko) * | 2015-10-07 | 2018-04-09 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
| PE20210043A1 (es) * | 2018-01-08 | 2021-01-08 | Gi Innovation Inc | Dominio extracelular de subunidad alfa del receptor fc de ige, composicion farmaceutica que comprende el mismo y metodo para producir el mismo |
| KR102038672B1 (ko) * | 2018-01-08 | 2019-10-30 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
| ES2969110T3 (es) * | 2018-01-12 | 2024-05-16 | Gi Innovation Inc | Composición que comprende probióticos y polipéptidos que tienen afinidad de unión por IgE y uso de la misma |
-
2020
- 2020-07-07 BR BR112022000246A patent/BR112022000246A2/pt unknown
- 2020-07-07 CA CA3145382A patent/CA3145382A1/en active Pending
- 2020-07-07 US US17/625,668 patent/US20220257693A1/en active Pending
- 2020-07-07 JP JP2021575270A patent/JP2022539684A/ja active Pending
- 2020-07-07 MX MX2022000285A patent/MX2022000285A/es unknown
- 2020-07-07 EP EP20837726.7A patent/EP3998279A4/en active Pending
- 2020-07-07 PE PE2022000024A patent/PE20220098A1/es unknown
- 2020-07-07 KR KR1020200083486A patent/KR102561135B1/ko active IP Right Grant
- 2020-07-07 AU AU2020310003A patent/AU2020310003A1/en active Pending
- 2020-07-07 WO PCT/KR2020/008855 patent/WO2021006599A1/ko unknown
- 2020-07-08 TW TW109123074A patent/TWI764191B/zh active
-
2021
- 2021-12-17 CL CL2021003401A patent/CL2021003401A1/es unknown
-
2022
- 2022-01-06 IL IL289679A patent/IL289679A/en unknown
- 2022-01-14 ZA ZA2022/00738A patent/ZA202200738B/en unknown
-
2023
- 2023-07-24 KR KR1020230096002A patent/KR20230115283A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210006293A (ko) | 2021-01-18 |
| AU2020310003A1 (en) | 2022-01-06 |
| TW202116799A (zh) | 2021-05-01 |
| ZA202200738B (en) | 2023-11-29 |
| WO2021006599A1 (ko) | 2021-01-14 |
| KR102561135B1 (ko) | 2023-07-31 |
| KR20230115283A (ko) | 2023-08-02 |
| CL2021003401A1 (es) | 2022-10-14 |
| CA3145382A1 (en) | 2021-01-14 |
| EP3998279A4 (en) | 2023-01-18 |
| BR112022000246A2 (pt) | 2022-02-22 |
| MX2022000285A (es) | 2022-02-03 |
| EP3998279A1 (en) | 2022-05-18 |
| TWI764191B (zh) | 2022-05-11 |
| IL289679A (en) | 2022-03-01 |
| US20220257693A1 (en) | 2022-08-18 |
| CN114080398A (zh) | 2022-02-22 |
| JP2022539684A (ja) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211202A1 (es) | Composiciones de glp-1 y sus usos | |
| BR112013032630A2 (pt) | polipeptídeo heterodimerizado | |
| BR112022009110A2 (pt) | Polipeptídeos de citocina ativáveis e métodos de uso destes | |
| CL2020001798A1 (es) | Dominio extracelular de una subunidad alfa del receptor fc para ige, composición farmacéutica que lo comprende y método para su producción. | |
| CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
| CO2018014026A2 (es) | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica | |
| UY33034A (es) | Materiales y métodos para el tratamiento o prevención de enfermedades asociadas al her-3 | |
| BRPI0609797B8 (pt) | nanocorpos melhorados para o tratamento de desordens mediadas por agregação | |
| BRPI0607490A2 (pt) | anticorpos monoclonais antiinterferon alfa e métodos para uso | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
| PE20191836A1 (es) | Compuesto de insulina acilada | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| DOP2017000248A (es) | PROTEÍNA DE UNIÓN A RGMa Y SU USO | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| PE20220098A1 (es) | Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| BR112021024285A2 (pt) | Vetores aav com promotor da proteína zero da mielina e usos dos mesmos para tratar doenças associadas a células de schwann como doença de charcot marie tooth | |
| CL2023000004A1 (es) | Formulación en concentración alta de proteínas de unión a antígeno del factor xii | |
| BR112013025975A2 (pt) | proteína de fusão anticancerígena | |
| WO2008134445A8 (en) | Platelet activation receptor clec-2: compositions and uses thereof | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| BR112015017909A2 (pt) | redução do risco de doença autoimune | |
| BR112021009912A2 (pt) | Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1 | |
| BR112021013096A2 (pt) | Tratamento de doença de sjögren com proteínas de fusão de nuclease | |
| BR112017025189A2 (pt) | composição e usos da mesma |